Home - Products - Others - Other Targets - Farnesylacetonemixture of isomers

Farnesylacetonemixture of isomers

CAS No. 762-29-8

Farnesylacetonemixture of isomers( ——— )

Catalog No. M38824 CAS No. 762-29-8

Farnesylacetonemixture of isomers

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Farnesylacetonemixture of isomers
  • Note
    Research use only, not for human use.
  • Brief Description
    Farnesylacetonemixture of isomers
  • Description
    Farnesylacetonemixture of isomers
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    762-29-8
  • Formula Weight
    262.43
  • Molecular Formula
    C18H30O
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Parishin C

    Parishin C is a phenolic glycoside and a major component of G. elata have antioxidant property.

  • α-Galactosylceramide

    α-Galactosylceramide is a synthetic glycolipid with antitumorial and immunostimulatory and is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide and CD1d can bind to the T cell antigen receptor of NKT cells.

  • (Ser4,Ile8)-Oxytocin

    Isotocin ((Ser4,Ile8)-Oxytocin) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.